Zobrazeno 1 - 10
of 123
pro vyhledávání: '"Hibiki Udagawa"'
Autor:
Motohiro Izumi, Masanori Fujii, Ikei S. Kobayashi, Vivian Ho, Yukie Kashima, Hibiki Udagawa, Daniel B. Costa, Susumu S. Kobayashi
Publikováno v:
Cell Death and Disease, Vol 15, Iss 8, Pp 1-11 (2024)
Abstract In EGFR-mutated lung cancer, the duration of response to tyrosine kinase inhibitors (TKIs) is limited by the development of acquired drug resistance. Despite the crucial role played by apoptosis-related genes in tumor cell survival, how thei
Externí odkaz:
https://doaj.org/article/0b4880c0b7b44dc7aa9de281cdad4388
Autor:
Shunta Mori, Hiroki Izumi, Mitsugu Araki, Jie Liu, Yu Tanaka, Yosuke Kagawa, Yukari Sagae, Biao Ma, Yuta Isaka, Yoko Sasakura, Shogo Kumagai, Yuta Sakae, Kosuke Tanaka, Yuji Shibata, Hibiki Udagawa, Shingo Matsumoto, Kiyotaka Yoh, Yasushi Okuno, Koichi Goto, Susumu S. Kobayashi
Publikováno v:
Communications Biology, Vol 7, Iss 1, Pp 1-10 (2024)
Abstract The CLIP1-LTK fusion was recently discovered as a novel oncogenic driver in non-small cell lung cancer (NSCLC). Lorlatinib, a third-generation ALK inhibitor, exhibited a dramatic clinical response in a NSCLC patient harboring CLIP1-LTK fusio
Externí odkaz:
https://doaj.org/article/d5116c53bf5a493298d2e20157408e3f
Autor:
Hibiki Udagawa, Shunji Takahashi, Motohiro Hirao, Makoto Tahara, Satoru Iwasa, Yasuyoshi Sato, Takuya Hamakawa, Kohei Shitara, Hidehito Horinouchi, Keisho Chin, Norikazu Masuda, Takuya Suzuki, Shiori Okumura, Takao Takase, Reiko Nagai, Kan Yonemori
Publikováno v:
Cancer Medicine, Vol 12, Iss 2, Pp 1269-1278 (2023)
Abstract Background In this open‐label, Phase 1 study, we explore the safety and efficacy of E7389‐LF (liposomal formulation of eribulin) in Japanese patients with advanced solid tumors. Methods This open‐label, Phase 1 study enrolled Japanese
Externí odkaz:
https://doaj.org/article/73b26d485732490b8b8d2a682fc73707
Autor:
Yosuke Kagawa, MD, Takuma Hayashida, MS, Jie Liu, BS, Shunta Mori, MD, Hiroki Izumi, MD, PhD, Shogo Kumagai, MD, PhD, Hibiki Udagawa, MD, PhD, Noboru Hattori, MD, PhD, Koichi Goto, MD, PhD, Susumu S. Kobayashi, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 3, Pp 100462- (2023)
Introduction: EGFR exon 20 insertion mutations account for 5% to 10% of EGFR-mutated NSCLC. CLN-081 (formerly known as TAS6417), a novel covalent EGFR tyrosine kinase inhibitor, exhibits pan-mutation selective efficacy, including exon 20 insertions,
Externí odkaz:
https://doaj.org/article/e3d98b0bb20a49d68b4a9a9c19b6c29e
Autor:
Kaho Miura, Yoshiyuki Sano, Seiji Niho, Kenji Kawasumi, Nobuo Mochizuki, Kiyotaka Yoh, Shingo Matsumoto, Yoshitaka Zenke, Takaya Ikeda, Kaname Nosaki, Keisuke Kirita, Hibiki Udagawa, Koichi Goto, Toshikatsu Kawasaki, Kazuhiko Hanada
Publikováno v:
Thoracic Cancer, Vol 12, Iss 13, Pp 1983-1994 (2021)
Abstract Background It has recently been suggested that concomitant medication may affect the clinical outcome of patients treated with immune checkpoint inhibitors (ICIs). However, only a few studies on the impact of concomitant medication on immune
Externí odkaz:
https://doaj.org/article/c2b2b23ff3964b8ba27171c6dc3821fb
Autor:
Hui Yang, Stephane Champiat, Ramaswamy Govindan, Ravi Salgia, Fiona Blackhall, Everett Vokes, Michael Boyer, Marie-Anne Damiette Smit, Melissa Johnson, Hossein Borghaei, Luis Paz-Ares Rodrigues, Rene Boosman, Horst-Dieter Hummel, W Victoria Lai, Hibiki Udagawa, Anne Chiang, Christine Hann, Mukul Minocha, Nooshin Hashemi-Sadraei, Aditya Shetty, Taofeek Owonikoko
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/f2567de972aa4a01b4c2c02dfa5cecc2
Autor:
Yuzo Sato, Shiori Matsuda, Ami Maruyama, Joji Nakayama, Tomoyuki Miyashita, Hibiki Udagawa, Shigeki Umemura, Kazuyoshi Yanagihara, Atsushi Ochiai, Masaru Tomita, Tomoyoshi Soga, Katsuya Tsuchihara, Hideki Makinoshima
Publikováno v:
Frontiers in Pharmacology, Vol 9 (2018)
Antifolates are a class of drugs effective for treating malignant pleural mesothelioma (MPM). The majority of antifolates inhibit enzymes involved in purine and pyrimidine synthesis such as dihydrofolate reductase (DHFR), thymidylate synthase (TYMS),
Externí odkaz:
https://doaj.org/article/ee31766fec794ef697c6af12fa10b995
Autor:
Akira Sugimoto, Shingo Matsumoto, Hibiki Udagawa, Ryo Itotani, Yuko Usui, Shigeki Umemura, Kazumi Nishino, Ichiro Nakachi, Shoichi Kuyama, Haruko Daga, Satoshi Hara, Shingo Miyamoto, Terufumi Kato, Jun Sakakibara-Konishi, Eriko Tabata, Taku Nakagawa, Tomoya Kawaguchi, Tetsuya Sakai, Yuji Shibata, Hiroki Izumi, Kaname Nosaki, Yoshitaka Zenke, Kiyotaka Yoh, Koichi Goto
Publikováno v:
Clinical Cancer Research. 29:1506-1514
Purpose: We evaluated plasma cell-free DNA (cfDNA) and tissue-based sequencing concordance for comprehensive oncogenic driver detection in non–small cell lung cancer (NSCLC) using a large-scale prospective screening cohort (LC-SCRUM-Liquid). Experi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6cc897d5d43308fd6f8fe4d851c8d24
https://doi.org/10.1158/1078-0432.ccr-22-1749
https://doi.org/10.1158/1078-0432.ccr-22-1749
Autor:
Shunichi Sugawara, Kentaro Tanaka, Fumio Imamura, Nobuyuki Yamamoto, Makoto Nishio, Kyoichi Okishio, Tomonori Hirashima, Hiroshi Tanaka, Tatsuro Fukuhara, Yasuharu Nakahara, Takayasu Kurata, Nobuyuki Katakami, Morihito Okada, Hidehito Horinouchi, Hibiki Udagawa, Kazuo Kasahara, Miyako Satouchi, Hideo Saka, Takaaki Tokito, Yukio Hosomi, Keisuke Aoe, Kazuma Kishi, Kadoaki Ohashi, Takuma Yokoyama, Noriaki Adachi, Kazuo Noguchi, Paul Schwarzenberger, Terufumi Kato
Publikováno v:
Cancer Science.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::279a9ff69ffa968307625fd22e41de5e
https://doi.org/10.1111/cas.15816
https://doi.org/10.1111/cas.15816
Autor:
Koichi Goto, Kiyotaka Yoh, Yoshitaka Zenke, Kaname Nosaki, Hiroki Izumi, Yuji Shibata, Tetsuya Sakai, Tomoya Kawaguchi, Taku Nakagawa, Eriko Tabata, Jun Sakakibara-Konishi, Terufumi Kato, Shingo Miyamoto, Satoshi Hara, Haruko Daga, Shoichi Kuyama, Ichiro Nakachi, Kazumi Nishino, Shigeki Umemura, Yuko Usui, Ryo Itotani, Hibiki Udagawa, Shingo Matsumoto, Akira Sugimoto
Purpose:We evaluated plasma cell-free DNA (cfDNA) and tissue-based sequencing concordance for comprehensive oncogenic driver detection in non–small cell lung cancer (NSCLC) using a large-scale prospective screening cohort (LC-SCRUM-Liquid).Experime
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33abd86977c89fe640712ac7d1e0e1d8
https://doi.org/10.1158/1078-0432.c.6532737.v2
https://doi.org/10.1158/1078-0432.c.6532737.v2
